Primary Analysis of MOUNTAINEER: A Phase 2 Study of Tucatinib and Trastuzumab for HER2-positive mCRC


Dr Tanios Bekaii-Saab reviews data from the MOUNTAINEER trial on combination tucatinib/trastuzumab in patients with HER2-positive metastatic colorectal cancer.

Related Videos
Marwan G. Fakih, MD
Howard S. Hochster, MD
Daneng Li, MD
Arvind Dasari, MD, MS, an expert on colorectal cancer
Megan Hitchins, PhD
Whitney S. Graybill, MD, MS, an expert on ovarian cancer
Marwan G. Fakih, MD
Scott Kopetz, MD, PhD, FACP
Related Content